Top Tweets for #BioconForBiologics
@CNBCTV18News @ETNOWlive @bsindia @FinancialXpress @FT @moneycontrolcom @businessline @business @CNNBusiness #BioconQ2FY20: Robust growth of 40% by #Biologics & 23% by Small Molecules. Steady performance by Research Services business with 11% growth in #Q2FY20. #BioconForBiologics #FinancialResults #Biocon #Results #Earnings https://t.co/664pMeG2fh
#Biologics #Research Facility at TICEL Chennai, is in addition to @Bioconlimited existing 2lac sqft RnD center at Bengaluru, would accelerate its global #biosimilars development programs. #AffordableAccess #BioconforBiologics
#HappyToShare: Biocon’s subsidiary #BioconBiologics is expanding its R&D footprint through a 60,000 sq ft state-of-the art 'bench to pilot scale' #Biologics research facility at TICEL Bio Park Chennai, India. Read more >> https://t.co/xZK7oHh6m3 #Biocon
The 41st Annual General Meeting of #Biocon is ready to start! #Biocon #JourneyOfFortitude #BioconForBiologics
#Watch: @kiranshaw briefing media on #Q1FY20 financial #results. #CMDSpeaks #BioconQ1FY20 #BioconForBiologics #Q1Earnings https://t.co/7qzwr938rj
All set for Biocon's 41st Annual General Meeting at 3:30PM today! #Biocon #JourneyOfFortitude #BioconForBiologics
Robust performance by #Biologics and Small Molecules business segments in #Q1FY20. Research Services business continues to provide profitable growth. Revenue at Rs 1,490 Cr, up 25%. #Q1FY20. #BioconForBiologics #FinancialResults #Results #Q1Earnings
#BioconQ1FY20: #Biocon delivers strong revenue growth of 25% led by 96% growth by #Biologics at Rs 490 Cr & 20% growth by Small Molecules at Rs 480 Cr. Net profit at 223 Cr, up 86%. EBITDA up 51% at 462 Cr. #Q1FY20. #BioconForBiologics #FinancialResults #Results #Q1Earnings
#NewBlog on Dr. S Ramanan, VP , Global Regulatory Affairs #Biocon, presentation at #USFDA Public Hearing on the Future of Insulin Biosimilars & Enabling #AffordableAccess to #patients. #BioconForBiologics https://t.co/iRPbJ8aZUc
#HappyToShare #Biocon #Mylan to present final Overall Survival Data from #HERITAGE study for Ogivri™ (trastuzumab-dkst), a #biosimilar to Herceptin® at #ASCO2019 Annual Meeting on June 2 in Chicago. #BioconForBiologics
Read more: https://t.co/XIJsOm9hVA
Dr Sundar R, VP Global Regulatory Affairs #Biocon presentation on'Patients- First, Science Based Regulatory Approaches for #Insulins' at #USFDA Public Hearing on Insulins on May13, drew a lot of attention. Enabling #PatientAccess is core to #BioconforBiologics
#Bioconforbiologics Committed to enable #patient #access to #biosimilars Extended in- licensing arrangements for #Hulio, #biosimilar #Adalimumab for global markets augurs well for #patients #business n all #partners @Bioconlimited #Mylan n #FKB
#Biocon & #Mylan accelerate commercialization of #biosimilar #Adalimumab in global markets, through inlicensed #Hulio from #FKB. Biocon retains economic interest & will gain a profit share in all markets. #BioconforBiologics
#Biocon & #Mylan accelerate commercialization of #biosimilar #Adalimumab in global markets, through inlicensed #Hulio from #FKB. Biocon retains economic interest & will gain a profit share in all markets. #BioconforBiologics
#CMDSpeaks @kiranshaw #Biocon reports a strong #FY19 #Revenue up 31% at Rs 5,659 Cr; Net Profit Up 143% at Rs 905 Cr. Also a landmark year for the #biosimilars business with revenues doubling this year! Read: https://t.co/X7oqE9hwBH #BioconForBiologics
Strong #BioconQ4FY19 performance led by robust growth in #Biologics and #ResearchServices businesses, supported by a significant growth in the #SmallMolecules business. Read: https://t.co/X7oqE9hwBH
#BioconForBiologics
#Bioconforbiologics uses its expertise in novels to build strong credibility in the world of #biosimilars developing #affordable #biologics for unmet #patients needs in #Developed n #EmergingMarkets Committed to enabling affordable #access2medicines @livemint
Biocon’s strategy of commercialising biosimilars through an established partner in the developed markets continues to yield benefits, writes @sree_rsr
https://t.co/Z1xiI15QxQ
#BioconQ3FY19 Our #Biosimilars performance during #Q3FY19 were driven by a strong performance across our portfolio of insulins, monoclonal antibodies (MAbs) and other biologics in key developed and emerging markets. Read: https://t.co/q7eqGZxX6M #BioconForBiologics
Congrats to @Bioconlimited and @kiranshaw
Making a mark in the #Biologics world, showing the capabilities of Indian R&D globally #BioconForBiologics
#Biocon delivers the highest ever #Revenue and #Profit growth in absolute terms in #Q3FY19. Revenue at Rs 1,566 Cr, Up 43%; Net Profit at Rs 217 Cr, Up 136% EBITDA at Rs 406 Cr, Up 59%. Biologics up 136% Read: https://t.co/q7eqGZxX6M
#BioconQ3FY19 #BioconForBiologics
#HappyToShare #Biosimilar #Trastuzumab developed by #Biocon n #Mylan receives approval in the #EU. #Ogivri received #EMA CHMP nod earlier in 2018. #BioconForBiologics committed to #AaffordableAccess to #quality #biosimilars #cancercare
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.7M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
88.9M followers
Taylor Swift
@taylorswift13
82.8M followers
Lady Gaga
@ladygaga
74.3M followers
Virat Kohli
@imvkohli
71.8M followers
Kim Kardashian
@kimkardashian
70.4M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.7M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers